The naturally occurring peptide GLP-1 is hypothesized to decrease blood sugar levels and improve insulin production; Semaglutide is a derivative of this peptide. In addition to reducing or preventing the consequences of Alzheimer’s disease, research suggests that Semaglutide may also enhance the function of the heart, liver, and lungs. Semaglutide is speculated to reduce hunger considerably by lowering intestinal motility and postponing gastric emptying.
Semaglutide Peptide: What is it?
Glucagon-like peptide-1, or GLP-1 for short, is a naturally occurring peptide hormone that is quite short, measuring just 30-31 amino acids. Its principal physiological effect is theorized as reducing blood sugar levels by naturally increasing insulin production. In addition to its alleged neurotrophic potential on the brain and central nervous system, it seems to promote insulin gene transcription, which protects beta-cell insulin reserves. Studies in the gastrointestinal tract have suggested that GLP-1 may considerably suppress hunger by lowering intestinal motility and postponing stomach emptying. As suggested by preliminary studies, GLP-1 may affect not just the cardiovascular system but also fatty tissue, bones, muscles, the liver, the lungs, and the kidneys.
Research on GLP-1 has mostly focused on its potential uses in the context of diabetes and suppressing hunger. The possible cardiovascular properties of the peptide are the primary focus of the secondary study. The potential of GLP-1 to prevent neurodegenerative disease is the subject of more recent, and thus weaker, studies. With the speculation that GLP-1 may delay or halt the buildup of amyloid beta plaques in the context of Alzheimer’s disease, this latter field of inquiry is the most recent and rapidly expanding subfield of GLP-1 research.
Semaglutide Peptide and the Brain
Data suggests that GLP-1 may aid learning and protect neurons from neurodegenerative illnesses like Alzheimer’s. One research purported that GLP-1 may improve learning deficiencies in mice with certain genetic abnormalities and improve associative and spatial learning in wild-type mice. Learning and memory appear much improved in rats compared to their normal counterparts when the GLP-1 receptor is overexpressed in certain brain areas.
Further studies in mice have hinted that GLP-1 may mitigate excitotoxic neuron damage and entirely shield rat neurodegeneration models from glutamate-induced cell death. The peptide has been hypothesized to promote neurite outgrowth in cells grown in a lab. Researchers are keeping their fingers crossed that further studies on GLP-1 will find a way to utilize it to stop or even reverse certain forms of neurodegeneration.
Surprisingly, GLP-1 and its counterpart exendin-4 have been assumed to decrease brain amyloid-beta and the beta-amyloid precursor protein in neurons in mice models. The main component of the plaques seen in Alzheimer’s disease is amyloid beta. While the exact cause of the plaques is unknown, they are linked to the severity of the illness. This study provides an intriguing insight as to how researchers may intervene in the development of moderate cognitive impairment to full-blown Alzheimer’s disease, but whether or not blocking amyloid beta formation will protect against the consequences of the illness is still up in the air.
Semaglutide Peptide and the Heart
New research has proposed that Semaglutide-receptors may be found throughout the heart and may enhance cardiac function in some situations by increasing heart rate and decreasing left ventricular end-diastolic pressure. Although it may not seem significant, elevated left ventricular end-diastolic pressure is linked to left ventricular hypertrophy, cardiac remodeling, and, ultimately, heart failure.
More recent research has even hinted that GLP-1 may help reduce total heart attack damage. The peptide seems to enhance glucose absorption in cardiac muscle, which aids the battling cells of ischemic heart muscle in obtaining the nutrients necessary for continued activity and prevention of programmed cell death. These cells seem to be insulin-independent in their enhanced glucose absorption.
Canines presented with large concentrations of GLP-1 appeared to have better left ventricular function and lower systemic vascular resistance. Investigations purport that as a consequence of the second effect, blood pressure might be reduced, which is good for the heart. Subsequently, this may have the potential to mitigate LV remodeling, vascular thickening, and heart failure, which are long-term effects of hypertension. In a study conducted on animals, Dr. Holst speculated that giving GLP-1 after a heart attack “constantly increased myocardial performance.”
Semaglutide Peptide and Appetite
It has been theorized in animal models that giving GLP-1 or a related substance into the brains of mice may decrease their appetite and prevent them from eating as much. There is speculation that GLP-1 may have the opposite effect of its intended effect on appetite by reducing the hunger hormone signaling in the animal models for longer. Recent animal investigations have purported that GLP-1 receptor agonists may induce a linear reduction in body weight.
Buy Semaglutide if you are a licensed professional researching this research compound. None of the substances mentioned in this article have been approved for human or animal consumption. Do not purchase or use peptides if you are not a licensed professional looking to test these peptides in a contained laboratory environment for scientific purposes.
References
[i] “The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. – PubMed – NCBI.” [Online].
[ii] “Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with… – PubMed – NCBI.” [Online].
[iii] “Cardiac function in mice lacking the glucagon-like peptide-1 receptor. – PubMed – NCBI.” [Online].
[iv] “Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury | Diabetes.” [Online].
[v] “Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-ind… – PubMed – NCBI.” [Online].
[vi] “Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. – PubMed – NCBI.” [Online].
[vii] “Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. – PubMed – NCBI.” [Online].
[viii] “A new Alzheimer’s disease interventive strategy: GLP-1. – PubMed – NCBI.” [Online].
David Prior
David Prior is the editor of Today News, responsible for the overall editorial strategy. He is an NCTJ-qualified journalist with over 20 years’ experience, and is also editor of the award-winning hyperlocal news title Altrincham Today. His LinkedIn profile is here.
